Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Self-Driving EV and Tech (IDRV) vs Novartis AG (NVS) Price & Performance

iShares Self-Driving EV and TechTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

iShares Self-Driving EV and Tech vs Novartis AG — how do they compare? iShares Self-Driving EV and Tech trades at $37.53, while Novartis AG trades at $152.73 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares Self-Driving EV and Tech pays none, and Novartis AG is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.

IDRVNVS
Sector
Sector/ThematicHealth
52-Week High
$45.48$168.62
52-Week Low
$34.49$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Self-Driving EV and Tech

No Aura AI signal available yet.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Self-Driving EV and Tech

IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.

Read more on IDRV

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS